Actualités et vidéos - ABIVAX - Anglais - Page 3

PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax announces trading resumption of its ordinary shares on Euronext Paris 20.10.2023 / 15:45 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, October 20, 2023 – 03:45 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on...

EQS-News: ABIVAX / Key word(s): IPO Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 20.10.2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market PARIS, France, October 20, 2023 – 3:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company...

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on Euronext in Paris (" Euronext Paris ") as from 4:20 p.m. CEST. Trading of the ordinary shares of Abivax...

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New...

EQS-News: ABIVAX / Key word(s): Temporary Suspension Abivax announces temporary trading halt of its ordinary shares on Euronext Paris 20.10.2023 / 08:45 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, October 20, 2023 – 08:45 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology...

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext in Paris (" Euronext Paris ") will be temporarily halted, at the Company's...

EQS-News: ABIVAX / Key word(s): IPO Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range 19.10.2023 / 00:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range PARIS, France, October 18, 2023 – 11:55 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“...

PARIS, FRANCE / ACCESSWIRE / October 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public...

EQS-News: ABIVAX / Key word(s): IPO Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing 16.10.2023 / 17:40 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing PARIS, France, October 16, 2023 – 05:40 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a...

PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the...

EQS-News: ABIVAX / Key word(s): Study results Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023 02.10.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023 Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to...

Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of a single microRNA, miR-124, in blood of obefazimod-treated UC patients Poster presentation on long-term enhanced expression of miR-124 in blood and rectal tissue of obefazimod-treated UC patients PARIS,...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax files registration statement for proposed initial public offering in the United States 29.09.2023 / 23:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax files registration statement for proposed initial public offering in the United States PARIS, France, September 29, 2023 – 11:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage...

EQS-News: ABIVAX / Key word(s): Half Year Report Abivax announces the release of its 2023 half-year financial report 29.09.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the release of its 2023 half-year financial report PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing...

EQS-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2023 financial results 21.09.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax presents first-half 2023 financial results PARIS, France, September 21, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s...

PARIS, FRANCE / ACCESSWIRE / September 21, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today its 2023 half-year financial results, as of June 30, 2023. The interim financial statements for the first half of 2023, approved by the Company's...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax provides business and operational update 07.09.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax provides business and operational update ABTECT Phase 3 Global Clinical Trial Enrollment Progressing as Planned; Induction and Maintenance Data Readouts Expected in Q1 2025 and Q1 2026, Respectively Durability of Efficacy Results with No New Safety Signals Observed in Step-Down Dosing from 50 mg to...

EQS-News: ABIVAX / Key word(s): Personnel Abivax appoints Patrick Malloy as Senior Vice President Investor Relations 23.08.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax appoints Patrick Malloy as Senior Vice President Investor Relations PARIS, France, August 23, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”) today announced the appointment of Patrick Malloy as new Senior...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax secures up to EUR 150M from two structured debt financing transactions 21.08.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax secures up to EUR 150M from two structured debt financing transactions Up to EUR 75M from Kreos Capital and Claret European Growth Capital Up to EUR 75M from Heights Capital Management EUR 27M of additional cash resources for Abivax at drawdown of the first tranches...